metabolic health

Does Safflower Oil Cardiometabolic Markers Randomized Trial work?

Updated October 2026

Quick Answer

Safflower Oil Cardiometabolic Markers Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: However, we have lacked data on sexual dimorphism in the response of cardiometabolic risk markers following increased consumption of n-3 or n-6 PUFAs.

Key Takeaways

  • 01However, we have lacked data on sexual dimorphism in the response of cardiometabolic risk markers following increased consumption of n-3 or n-6 PUFAs. [Laupsa-Borge J (2023)]
  • 02Background Clinical studies on effects of marine-derived omega-3 (n-3) polyunsaturated fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and the plant-derived omega-6 (n-6) PUFA linoleic acid (LA) on lipoprotein-lipid components and glucose-insulin homeostasis have shown conflicting results, which may partly be explained by differential responses in females and males. [Laupsa-Borge J (2023)]
The current Migaku evidence database contains 1 reusable source document for Safflower Oil Cardiometabolic Markers Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - However, we have lacked data on sexual dimorphism in the response of cardiometabolic risk markers following increased consumption of n-3 or n-6 PUFAs. [Laupsa-Borge J (2023); evidence level 2] - Background Clinical studies on effects of marine-derived omega-3 (n-3) polyunsaturated fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and the plant-derived omega-6 (n-6) PUFA linoleic acid (LA) on lipoprotein-lipid components and glucose-insulin homeostasis have shown conflicting results, which may partly be explained by differential responses in females and males. [Laupsa-Borge J (2023); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Learn next

Keep learning from this answer

GuideProbiotics: What the Evidence Actually Supports (and What It Doesn't)Legacy library material — check the original sources.GuideCreatine: Complete Guide to Dosage, Loading, and What It Does for PerformanceLegacy library material — check the original sources.GuideVitamin C: High-Dose Supplementation — What It Does and Doesn't DoLegacy library material — check the original sources.GuideImmune Support Protocol: What Actually Works vs What Doesn'tLegacy library material — check the original sources.CompareFish Oil Omega-3 vs Algae Omega-3Legacy library material — check the original sources.DataSafflower Oil Cardiometabolic Markers Randomized Trial Evidence TableLegacy library material — check the original sources.DataOlive Oil Cardiometabolic Markers Randomized Trial Evidence TableLegacy library material — check the original sources.DataOlive Leaf Extract Cardiometabolic Markers Meta-Analysis Evidence TableLegacy library material — check the original sources.

Sources

  1. Sex-specific responses in glucose-insulin homeostasis and lipoprotein-lipid components after high-dose supplementation with marine n-3 PUFAs in abdominal obesity: a randomized double-blind crossover study.